Deciding between Active Surveillance and Immediate Treatment for your prostate cancer is important. Your GPS test results can help.

The GPS test looks at prostate cancer genes to assess how aggressively your cancer will grow or spread. Since certain key genes influence this more than others, knowing which ones are active in your tumor helps determine your personal GPS result.

Your personal GPS result and risk category

Your score is based on a scale of 0-100. Your risk category can range from very low to high. These results give an overall picture of your cancer and its risk of growing or spreading.

SAMPLE REPORT:

**Current and future risk**

These results can predict both your chance of: 1) dying from prostate cancer and 2) your cancer spreading (metastasis) in the next 10 years.

**SAMPLE REPORT:**

1. Prostate Cancer Death Within 10 Years
   - <1%
   - (95% CI: <1% - <1%)

2. Metastasis Within 10 Years
   - 1%
   - (95% CI: <1% - 4%)

3. Adverse Pathology
   - 15%
   - (95% CI: 11% - 20%)

**3 Adverse Pathology** looks at how aggressive your tumor is right now. This helps your doctor know if you are a candidate for Active Surveillance or if Immediate Treatment is best for you.
Oncotype DX Genomic Prostate Score® (GPS™) assay

Personalized assessment for individualized treatment

Your GPS result compared to other patients
The bell curve illustrates where your GPS result falls in relation to other prostate cancer patients in the same risk category.

SAMPLE REPORT:

![GPS Distribution in NCCN® Low Risk](image)

Additional pathology endpoints
1. **High-Grade Disease** shows the likelihood that cancer cells within your tumor are abnormal when compared to typical cells.
2. **Non-Organ-Confined Disease** indicates the likelihood that your cancer has already spread outside your prostate.

SAMPLE REPORT:

<table>
<thead>
<tr>
<th>Pathology Endpoints</th>
<th>Individualized Risk (95% Confidence Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 High-Grade Disease (Gleason 3+4)</td>
<td>9% [95% CI: 6% - 13%]</td>
</tr>
<tr>
<td>2 Non-Organ-Confined Disease (pT3+)</td>
<td>10% [95% CI: 7% - 14%]</td>
</tr>
</tbody>
</table>

The GPS test provides a personalized assessment of your prostate cancer, helping you and your doctor discuss next steps with confidence.